Holen Sie sich die Stockscreener-App
7.65
1.42%
-0.11
Handel nachbörslich:
7.63
-0.02
-0.26%
Schlusskurs vom Vortag:
$7.76
Offen:
$7.57
24-Stunden-Volumen:
216.93K
Relative Volume:
1.64
Marktkapitalisierung:
$484.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-159.39M
KGV:
-
EPS:
-
Netto-Cashflow:
$-105.22M
1W Leistung:
+7.59%
1M Leistung:
-13.66%
6M Leistung:
-44.24%
1J Leistung:
-27.63%
1-Tages-Spanne:
$7.39
$7.83
1-Wochen-Bereich:
$7.39
$8.175
52-Wochen-Spanne:
$7.11
$17.02
Abivax Adr Stock (ABVX) Company Profile
Vergleichen Sie ABVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
7.65 | 484.53M | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | Laidlaw | Buy |
| 2024-05-20 | Eingeleitet | BTIG Research | Buy |
| 2024-04-29 | Eingeleitet | Guggenheim | Buy |
| 2024-04-29 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-14 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Abivax Adr Aktie (ABVX) Neueste Nachrichten
Abivax Initiates $150 Million ATM Program on Nasdaq - TipRanks
Abivax Reports Strong Q3 Financials and Clinical Progress - TipRanks
Check Out Abivax ADR (ABVX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Insider’s View: Deciphering Abivax ADR (ABVX)’s Financial Health Through Ratios - The Dwinnex
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewswire Inc.
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
DEADLINE ALERT for ABR, FIVE, DXC, and INDV: The Law - GlobeNewswire
Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade - MSN
Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax SA Reveals Soaring R&D Costs in H1 2024 - TipRanks
Inflammatory Bowel Disease Treatment Market Size Expected to Reach USD 33.19 Bn by 2032 - GlobeNewswire Inc.
Abivax SA Advances with Positive Trial OutcomesTipRanks.com - TipRanks
Abivax ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Abivax SA Secures Funding and Expands Operations - TipRanks
Finanzdaten der Abivax Adr-Aktie (ABVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):